ZILGANERSEN SODIUM
| Brand name | ZANVASTRO |
|---|---|
| Active ingredient | ZILGANERSEN SODIUM |
| Strength | EQ 56MG BASE/2.8ML (EQ 20MG BASE/ML) |
| Dosage form | SOLUTION |
| Route | INTRATHECAL |
| Modality | Small molecule |
| FDA approval | September 2026 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 11786546 | May 2041 | substance, product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.